US FDA Approves Etcamah for ESR1-Mutated Advanced Breast Cancer
The US FDA granted accelerated approval to Etcamah for advanced breast cancer with ESR1 mutations, and authorized Guardant360 CDx as a companion diagnostic.
The United States Food and Drug Administration (FDA) has granted accelerated approval to Etcamah for the treatment of advanced breast cancer that carries a specific genetic mutation in the ESR1 gene. The decision, announced on September 4, marks a targeted therapeutic option for patients whose tumours harbour this alteration.
In a related action, the FDA also authorised the Guardant360 CDx assay as a companion diagnostic for this indication. The blood-based test will help identify patients eligible for Etcamah by detecting the presence of ESR1 mutations.
Accelerated approval is a regulatory pathway that allows earlier availability of drugs for serious conditions where there is an unmet medical need, based on a surrogate endpoint that is reasonably likely to predict clinical benefit. Continued approval may be contingent upon confirmatory trials.
This development underscores the growing role of precision oncology, where treatments are matched to the molecular profile of a patient's cancer. ESR1 mutations are commonly associated with resistance to endocrine therapy in hormone-receptor-positive breast cancer, making this approval a notable step in addressing such resistance.